Biotech Companies Announce Upcoming Conferences, Appointments - Research Report on Illumina, Epizyme, Questcor Pharmaceuticals,

   Biotech Companies Announce Upcoming Conferences, Appointments - Research
Report on Illumina, Epizyme, Questcor Pharmaceuticals, Infinity, and Endocyte

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 19, 2013

NEW YORK, November 19, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Illumina
Inc. (NASDAQ: ILMN), Epizyme, Inc. (NASDAQ: EPZM), Questcor Pharmaceuticals,
Inc. (NASDAQ: QCOR), Infinity Pharmaceuticals Inc. (NASDAQ: INFI), and
Endocyte, Inc. (NASDAQ: ECYT). Today's readers may access these reports free
of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Illumina Inc. Research Report

On November 11, 2013, Illumina Inc. (Illumina) announced the appointment of
Francis deSouza to the role of President. According to the Company, deSouza
will report to CEO Jay Flatley and will lead Illumina's business units and the
core functions responsible for envisioning, developing and producing the
Company's products. deSouza will also become part of Illumina's executive
management team, which is responsible for directing all aspects of company
strategy, planning and operations. According to Illumina, deSouza has nearly
two decades of technology experience and has successfully brought products to
market in startups as well as large organizations. The Full Research Report on
Illumina Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/3cf2_ILMN

--

Epizyme, Inc. Research Report

On November 14, 2013, Epizyme, Inc. (Epizyme) announced initial findings from
an ongoing Phase 1 study of EPZ-5676, a potent and selective inhibitor of the
DOT1L histone methyltransferase (HMT) being developed for the treatment of
acute leukemia with alterations in the MLL gene. CEO Robert J. Gould, Ph.D.,
said, "EPZ-5676 is a first-in-class inhibitor of the DOT1L HMT, and we are
very pleased with the findings to date in the dose escalation stage of the
ongoing two-stage Phase 1 study. The safety, pharmacokinetic, pharmacodynamic,
and treatment effects observed in this study are consistent with our
pre-clinical data. Based on these results, we plan to initiate the MLL-r only
Phase 1 expansion stage in December 2013 and pediatric MLL-r and MLL-PTD
studies in early 2014." Based on the said results, Epizyme plans to start the
Phase 1 MLL-r only expansion stage with an 80 mg/m2/day administration
schedule without a drug holiday and with possible continued dose escalation.
The Company reported that this expansion stage is intended to provide an
initial assessment of efficacy for EPZ-5676 in MLL-r patients. The Full
Research Report on Epizyme, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/0d2e_EPZM

--

Questcor Pharmaceuticals, Inc. Research Report

On November 12, 2013, Questcor Pharmaceuticals, Inc. (Questcor) announced the
addition of G. Kelly Martin, President and CEO of Elan Corporation, plc, to
Questcor's Board of Directors Questcor informed that the addition has brought
the number of directors to eight, seven of whom are independent. According to
Questcor, Martin has served as Elan's President, CEO, and a member of its
Board of Directors since February 2003. The Company further informed that
during Martin's tenure, he led a strategic plan to restructure Elan's
business; built a diverse portfolio of scientific, clinical and therapeutic
assets; and improved Elan's balance sheet by eliminating $4.5 billion in debt
and obligations and strengthening its cash position. According to the Company,
Elan's market capitalization grew from approximately $500 million when Martin
joined Elan in February 2003 to over $8.5 billion when Elan announced its
proposed sale to Perrigo Inc. in July 2013. The Full Research Report on
Questcor Pharmaceuticals, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/a415_QCOR

--

Infinity Pharmaceuticals Inc. Research Report

On November 11, 2013, Infinity Pharmaceuticals Inc. (Infinity) announced that
its presentation at the Credit Suisse 2013 Healthcare Conference, originally
scheduled for November 13, 2013, has been rescheduled to November 12, 2013, at
10:00 a.m. ET (8:00 a.m. MT). The Full Research Report on Infinity
Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/3862_INFI

--

Endocyte, Inc. Research Report

On November 7, 2013, Endocyte, Inc. (Endocyte) announced that Colin Goddard,
Ph.D., has joined Endocyte's board of directors. According to the Company, Dr.
Goddard is CEO and Chairman of Coferon, Inc. (Coferon), a privately held
biotechnology company, and director of the biotech companies Agendia and
PanOptica as well as an advisor to venture capital firms. Prior to joining
Coferon, Dr. Goddard was CEO of OSI Pharmaceuticals (OSI), leading the company
through its transition from a technology platform to profitable
biopharmaceutical company, until its acquisition by Astellas Pharma for $4
billion. Dr. Goddard joined OSI as a scientist in 1989, and served as
President and Chief Operating Officer before assuming the CEO role in 1998.
The Full Research Report on Endocyte, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/fdf5_ECYT

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)